by Kyle LaHucik for Endpoints News

“Odysseus eventually made it to shore, as BridgeBio CEO Neil Kumar reminded the industry last Friday in a nod to Homer’s classic tale. And on Monday, his biotech celebrated a key Phase III win, putting wind in its sails for a trip to the FDA.

Biotechs everywhere are hoping for a similar moment in the sun after a two-year troubled odyssey beset by low rounds of private financing, misaligned valuation expectations, a largely unrewarding public market, and a death of IPOs…”

Continue reading at the original source, linked here.